COMy 2017: Day 2 discussion on relapsed myeloma, treatment, plasma cell leukemia and awards
Arnon Nagler et al.
Follow-up results of looking at treatment with ibrutinib on CLL patient survival and adverse events
Can the cytomegalovirus be predicted by ELISpot assays?
Targeting ROR1 and a two-drug approach to cure CLL
Overview of a promising new study of venetoclax in patients with CLL